Yellox 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

yellox

bausch + lomb ireland limited - brómfenak natríum sesquihýdrat - pain, postoperative; ophthalmologic surgical procedures - augnlækningar - meðferð við augnbólgu eftir aðgerð eftir útdráttur á drerum hjá fullorðnum.

Kyntheum 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

kyntheum

leo pharma a/s - brodalumab - psoriasis - Ónæmisbælandi lyf - kyntheum er ætlað til meðferðar á miðlungsmiklum til alvarlegum skellupsoriasis hjá fullorðnum sjúklingum sem eru frambjóðendur í almennri meðferð.

Reagila 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

reagila

gedeon richter - cariprazin hýdróklóríð - geðklofa - psycholeptics - reagila er ætlað til meðferðar á geðklofa hjá fullorðnum sjúklingum.

Byannli (previously Paliperidone Janssen-Cilag International) 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

byannli (previously paliperidone janssen-cilag international)

janssen-cilag international n.v.   - paliperidon palmitat - geðklofa - psycholeptics - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.

Nexpovio 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

nexpovio

stemline therapeutics b.v. - selinexor - mergæxli - Æxlishemjandi lyf - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Omnic Hart hylki með breyttan losunarhraða 0,4 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

omnic hart hylki með breyttan losunarhraða 0,4 mg

astellas pharma a/s* - tamsulosinum hýdróklóríð - hart hylki með breyttan losunarhraða - 0,4 mg